RAD 602

RAD 602 is a peptide–radionuclide conjugate radiopharmaceutical being developed as a first-in-class theranostic targeting brain cancers. It consists of a peptide directed against protein tyrosine phosphatase receptor type M (PTPRM, also known as PTPµ) linked to the beta-emitting radionuclide terbium-161, enabling targeted delivery of ionizing radiation to PTPRM-expressing tumor cells while also providing imaging capability.[3][7][11][13] Developed by Radiopharm Theranostics with terbium-161 isotope supply from TerThera, RAD 602 is designed for treatment of advanced brain tumors and has reached preclinical-stage development, with the aim of exploiting KLK/PTPRM-based biology for precision radiotherapy in oncology.[3][5][7][11][13]